The Oracle Of Omaha Finally Buys Into The AI Ad Machine

Berkshire just opened a multi-billion-dollar position in one of the biggest winners of the AI and online-ads boom, and the stock jumped. We’ll unpack what that signal really means, where the risks hide, and how to build a calm, long-term entry plan.

AI-driven innovation is expanding beyond the usual market favorites, opening
a new set of opportunities for investors paying attention.

A new FREE breakdown uncovers 9 companies with real revenue traction, active U.S. operations and deep AI alignment.

Each one sits in a rapidly shifting segment that could benefit from renewed regulatory clarity and domestic expansion.

Market interest is rising, and the next wave of capital may move fast.

Access the FREE Report

Futures are leaning higher to start the week, with the AI crowd trying to shake off last week’s valuation jitters while a Buffett-backed pop in a certain search-and-YouTube giant helps tech’s mood.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Premarket Earnings:

Aftermarket Earnings:

Economic Reports:

Walt Disney Co (NYSE: DIS) just told the world it wants to sprinkle generative AI all over Disney+, letting users make and share their own short-form creations, and the internet promptly grabbed its torches and pitchforks.

Fans and creators are worried this is less of a creative playground and more of cheap AI slop, with people calling for boycotts and reminding the House of Mouse that actual artists still like getting paid.

At the same time, Disney is in a loud carriage fight with YouTube TV, which means some sports fans can’t even watch ESPN’s biggest games without jumping apps or hunting for sketchy streams.

So you’ve got backlash from storytellers and irritation from the sports crowd, all while Disney is trying to prove its streaming strategy and park rebound are still on track.

Put simply, Disney’s still a powerhouse, but it feels like management is stress-testing how far they can push customers before they snap. That’s not a great look when the stock has already had a choppy year and investors would really just like boring, steady progress.

My Take For You: If you’re on the sidelines, wait to see if this AI push and the ESPN standoff actually move the needle on subs and profits, not just Twitter rants. If you already own shares, this is a don’t panic moment.

My Verdict: Solid long-term brand with self-inflicted headaches. Fine as a moderate-sized core name if you can ignore the noise, but not something to overload while management experiments in public.

Alphabet just got the kind of nod you can’t buy with ad dollars: Berkshire Hathaway quietly built a multi-billion-dollar stake, and the stock jumped as traders said, “Oh, now Grandpa likes Google.”

It’s a rare tech bet from the Buffett camp and comes right when everyone is arguing about whether AI spending has gone full bubble or just regular frothy.

The charm here is simple: Alphabet is one of the core players powering AI search, cloud, and ads, but it still trades a bit cheaper than some of the flashier chip names.

If you think AI is a more long-term shift than a short-term fad, owning the “picks and shovels plus ad machine” can feel more comfortable than chasing every new chip or startup.

Of course, Berkshire buying doesn’t mean the stock only goes up from here. AI budgets can get trimmed, regulators love poking big tech, and sentiment around expensive growth can flip fast.

But this is one of those names people reach for when they want quality in a noisy market.

My Take For You: If you’ve been waiting for a grown-up signal to start a position, seeing Berkshire step in may be your nudge. So start small, then add on pullbacks instead of chasing big green days.

My Verdict: High-quality tech anchor that could still compound over time. Makes sense as a long-term core holding, sized so you can sleep at night even when AI headlines swing from euphoria to doom.

What if you could see where the pros are focusing now?

A newly released 5-stock report uncovers the companies that analysts believe could deliver the strongest upside in 2025.

These names show strong growth, earnings acceleration, and major market catalysts that point toward potential triple-digit returns.

The opportunity window is narrow — access is free only until midnight tonight.

[Get the 5 Stocks Report Before Access Closes]

Jazz Pharmaceuticals just pulled off the biotech version of a sold-out show: its cancer drug Ziihera delivered strong results in a big late-stage trial for certain stomach and esophagus tumors, beating the current standard treatment and giving doctors a real reason to pay attention.

That’s why the stock is popping. This is data that could reshape a niche where patients badly need better options.

In plain English, the drug helped people go longer before their cancer got worse and, in one combo, helped them live longer overall. Now Jazz is lining up the next steps: more detailed data at big medical meetings and a push for regulators to sign off so this can become a first-choice treatment.

That road takes time, paperwork, and more scrutiny, but today’s news moves the company from promising to potential new standard territory.

For us, that means a more interesting pipeline, but also more wait-and-see. Regulators can be picky, competitors don’t stand still, and oncology launches are marathons, not sprints.

My Take For You: If you’re new to the name, don’t chase the first big pop; wait for the dust to settle and use the next pullback or data update as your decision point. If you’re already long, this is a good moment to take a little off the table.

My Verdict: Upgraded from background biotech to a credible growth story with catalysts. Fits best as a mid-sized, higher-risk position for investors comfortable with trial, regulatory, and launch ups and downs.

This biotech just hit the great news jackpot, with trial results showing its cancer drug could beat the current go-to option. That’s how you get a chart that looks like it drank three energy drinks before the open. It’s suddenly the new kid who might actually make varsity.

Just remember, stocks love to overreact to science headlines and then spend weeks rereading the fine print.

Clearwater’s jumping after chatter that private equity heavyweights might take it off the public market dance floor. Nothing gets a sleepy software stock moving like the words “in talks” and “buyout.” Suddenly, every share looks like it comes with a little takeover lottery stub attached.

But talks can drag, stall, or end in an awkward “we’ve decided to remain friends.”

Dell’s waking up on the wrong side of the bed after a big bank slapped it with a downgrade and worries that AI server costs are chewing into the story. After a huge multi-year run, this is the market’s way of saying “cool story bro”.

When expectations are sky-high, even a hint of less profit later can knock a favorite name down a few pegs.

Experienced investors often follow a clear framework when approaching fast-moving digital markets.

A new, free guide breaks down the three pillars shaping their decisions — from broad exposure strategies to targeted speculative moves.

The insights are designed for readers aiming to identify both steady trends and short-term bursts.

Access remains limited, and many investors are already requesting the guide.

This window may close sooner than expected.

Unlock the Free Crypto Guide Now

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.